Sat, Mar 02, 2024
"Aurobindo Pharma Limited is pleased to announce that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod Capsules, 0.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. The product will be launched in March 2024," said Aurobindo Pharma in a statement on Friday.
More >
Fri, Feb 12, 2021
Aurobindo Pharma Q3 FY21 revenue, operating profits and PAT were a tad below the estimates. Sales at Rs 6365 cr is up 8% yoy (slightly below estimates), attributable to an 11.3% yoy growth in the formulations segment, while API sales were down 13.6% yoy. OPM expanded by 100 BPS yoy to 21.5% (estimated OPM 22%) led by a 310 bps expansion in gross margins, which were partly offset by an increase in other expenses.
Mon, Jun 05, 2017
It has been a long and dreary quarter for pharmaceutical companies in Q4 wherein most posted a decline in net profit and things are not looking too good for the Indian pharma companies in the first half of FY18 as well.
Sat, Apr 30, 2016
The Foreign Investment Promotion Board (FIPB) in its meeting on Friday cleared 5 out of 14 proposal, a finance ministry official said.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.